Kythera Biopharmaceuticals

KYTHERA raises $37.4 million in Series D financing

Monday, September 19, 2011

KYTHERA Biopharmaceuticals has closed a $37.4M Series D financing round. The round featured significant new investments as well as participation from all existing institutional investors. Proceeds from this financing are slated to be used for conducting US phase III trials for KYTHERA’s lead product, ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.

[Read More]